CTABF - Canntab Therapeutics Limited

Canntab Therapeutics Limited

223 Riviera Drive
Suite 801
Markham, ON L3R 5J6
Canada
416-957-6303
http://canntab.ca

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jeffrey W. Renwick	CEO & Director	N/A	N/A	1968
Mr. Richard C. Goldstein	CFO & Director	N/A	N/A	1961
Mr. Barry M. Polisuk	Chairman & Corp. Sec.	N/A	N/A	1960
Mr. Robert Lefler	Director of Operations	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Canntab Therapeutics Limited, a cannabis oral dosage formulation company, researches and develops advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers extended release, flash melt, immediate release, modified release, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. The company was formerly known as Telferscot Resources Inc. and changed its name to Canntab Therapeutics Limited in April 2018. Canntab Therapeutics Limited was incorporated in 2010 and is headquartered in Markham, Canada.

Corporate Governance

Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.